June 30, 2008 - Nucletron today appointed Jos Lamers as its new CEO.

Lamers, a highly experienced international business executive, has a proven track record in life sciences and business-to-business fields, said the company. Prior to joining Nucletron, he held senior management and board positions at Numico, a top Europepean manufacturer of baby and infant related food products, and currently is a member of the executive board at Eurofins Scientific, an international laboratory group offering quality testing and support services.

June 30, 2008 - The Research Evaluation Committee has chosen the recipients of several awards and grants that are funded by the Radiation Oncology Institute (formerly the ASTRO Education and Development Fund) and distributed each year as part of the organization's overall effort to prevent, treat and cure malignancies.

June 30, 2008 – New research from Harvard University neuroscientists has pinpointed exactly how neural activity boosts blood flow to the brain, helping to better understand brain imaging techniques such as fMRI.

The research is described in the June 26 issue of the journal Neuron.

June 30, 2008 - Marion General Hospital of Marion, OH, signed a seven-year agreement for remote hosting services for GE Healthcare’s Centricity Enterprise solution, providing Marion General with the advanced capabilities of Centricity Enterprise, aiming to improve and streamline patient care, increase collaboration between clinicians and align their organization for clinical transformation.

June 30, 2008 - The Center for Radiation Therapy of Beverly Hills is the first medical center in California to commence treating cancer patients with a new technique utilizing RapidArc radiotherapy technology, aiming to deliver an advanced image-guided, intensity-modulated radiation therapy (IMRT) treatment two to eight times faster than is possible with conventional IMRT or helical tomotherapy.

June 30, 2008 - Acceleware Corp. is challenging researchers and clinicians to test the speed of its newest image construction solution, AxRecon, by submitting data via www.acceleware.com, gaining a first-hand demonstration of its data reconstruction.

June 30, 2008 - Scientists at Wake Forest University Baptist Medical Center said they are starting a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.

The treatment will involve transfusing specific white blood cells, called granulocytes, from select donors, into patients with advanced forms of cancer. A similar treatment using white blood cells from cancer-resistant mice has previously been highly successful, curing 100 percent of lab mice afflicted with advanced malignancies.

ArthroCare Corp. offers the DoublePlay implant, a suture anchor device intended for soft tissue to bone fixation in surgical procedures such as rotator cuff repair.

The DoublePlay device is a fully threaded anchor and features an “eyeless” design, a new concept in the world of screw-in anchors. The design eliminates the risk of eyelet breakage, the most common mode of failure in standard absorbable anchors.

The recently FDA-cleared ARTISTE linear accelerator from Siemens Healthcare has recently gone clinical in three prominent cancer centers around the world, according to Siemens. Dozens of patients have been treated to date at MAASTRO Clinic in the Netherlands, German Cancer Research Center (DKFZ) in Heidelberg, Germany, and Baton Rouge General’s Pennington Cancer Center in Louisiana.

June 27, 2008 - IntraOp Medical released the results of a study which shows that, for women with breast cancer, a single dose of intraoperative electron-beam radiation therapy (IOERT) can be equal to six weeks of traditional post-operative radiation therapy.

IntraOp’s Mobetron is the only FDA-approved self-shielding device offering IOERT treatment in the operating room in the U.S., said the company.

According to IntraOp, the results of this study mean:

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now